Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy

NIH RePORTER · NIH · R01 · $619,902 · view on reporter.nih.gov ↗

Abstract

Project Summary Recent preclinical and clinical results have demonstrated the safety and efficacy of nanoparticle-amplified radiation therapy. In parallel, MR-guided radiation therapy is an emerging paradigm that would benefit from specific contrast agents. This Academic- Industrial Partnership will leverage these current trends by designing, developing and rigorously testing a novel nanoparticle for MR-guided radiation therapy. Our supporting data consists of extensive physical and biological characterization of gadolinium and bismuth-gadolinium based nanoparticles, including in vivo biodistribution, imaging and therapy results in multiple tumor models. In this project, we will develop and optimize a direct high-yield synthesis process for bismuth-gadolinium nanoparticles and perform extensive toxicity and therapy evaluation in a translational model under clinical delivery schedules and conditions. Our innovative and highly translatable imaging and therapy concept is compatible with current and emerging clinical practice and could offer a substantial clinical benefit with minimal patient risk.

Key facts

NIH application ID
9971160
Project number
1R01CA240804-01A1
Recipient
DANA-FARBER CANCER INST
Principal Investigator
Ross I. Berbeco
Activity code
R01
Funding institute
NIH
Fiscal year
2020
Award amount
$619,902
Award type
1
Project period
2020-03-01 → 2025-02-28